haloperidol has been researched along with Hallucination of Body Sensation in 98 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on a 41 year old woman, who after 750 mg mefloquine, a newer antimalarial agent, developed a psychosis with dizziness, confusion and delusions." | 7.68 | [Psychotic episode caused by prevention of malaria with mefloquine. A case report]. ( Folkerts, H; Kuhs, H, 1992) |
| "Charles Bonnet syndrome is an underrecognized condition characterized by complex visual hallucinations, ocular problems causing visual deterioration and preserved cognitive status." | 5.35 | [Charles Bonnet syndrome: report of one case managed with haloperidol]. ( Franco, JG; Valencia, C, 2008) |
| "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation." | 5.08 | A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. ( Bell, K; Cooper, TB; Devanand, DP; Marder, K; Mayeux, R; Michaels, KS; Pelton, GH; Sackeim, HA; Sullivan, MA, 1998) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| " Auditory hallucinations had developed 25 years previously, for which haloperidol had been prescribed." | 3.74 | Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam. ( Inada, T; Oda, T; Yamamoto, N, 2007) |
| "We report on a 41 year old woman, who after 750 mg mefloquine, a newer antimalarial agent, developed a psychosis with dizziness, confusion and delusions." | 3.68 | [Psychotic episode caused by prevention of malaria with mefloquine. A case report]. ( Folkerts, H; Kuhs, H, 1992) |
| " But 2 days later he developed auditory hallucinations which were interpreted as alcohol hallucinations, for which he was additionally given haloperidol, 15 mg/d." | 3.68 | [Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses]. ( Eikmeier, G; Gastpar, M; Kastrup, O, 1991) |
| " Adjunctive treatment with clonazepam resulted in the cessation of the seizures and of persistent, violent hallucinations." | 3.67 | Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder. ( Keats, MM; Mukherjee, S, 1988) |
| "A report is made on two cases of a pharmacogenic delirium as a result of combined lithium-haloperidol therapy, and on one case of lithium-induced diabetes insipidus renales with second-degree high pressure." | 3.65 | [Dangerous side effects of lithium therapy]. ( Ehle, G; Uebelhack, R, 1977) |
| "About 30 patients with, in some cases, recurring paranoid or paranoid-hallucinatory psychoses underwent a long-term treatment--from 2--6 years according to individual cases--with very small doses of powerful neuroleptics (Haloperidol, Triperidol, and occasionally Trisedyl)." | 3.65 | [Neuroleptic long term care with extremely low doses in psychotic syndromes of paranoid-hallucination type]. ( König, L; Rossner, M, 1975) |
| "26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol." | 3.65 | Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. ( Ackenheil, M; Eben, E; Hippius, H; Rüther, E; Schilkrut, R, 1976) |
| " These two observations concern a treatment with Haloperidol at high dosages giving surprising effects: syndrom of excitement with an increase in delusive activity along with hallucinations and a touch of depressive mood." | 3.65 | [Paradoxical effects of neuroleptics]. ( Colonna, L, 1976) |
| "Auditory hallucinations are a characteristic symptom of schizophrenia and are usually resistant to treatment." | 2.74 | Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. ( Bagati, D; Nizamie, SH; Prakash, R, 2009) |
| "The drug difference between a low and a high dosage of haloperidol was investigated in 40 acutely ill schizophrenic patients." | 2.65 | Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder. ( Lehmann, E; Scholz, OB; Winter, M, 1984) |
| "If hallucinations are experienced during or after a period of alcohol abuse, the diagnosis of alcohol hallucinosis should be considered." | 1.42 | [Alcohol hallucinosis]. ( Blom, JD; Bouritius, EM; Neven, A, 2015) |
| "Haloperidol was discontinued, but mirtazapine was continued, and the vivid dream activity persisted; however, reality testing when awake was intact." | 1.36 | Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. ( Felthous, AR; Hoevet, R; Wenger, PJ, 2010) |
| "Charles Bonnet syndrome is an underrecognized condition characterized by complex visual hallucinations, ocular problems causing visual deterioration and preserved cognitive status." | 1.35 | [Charles Bonnet syndrome: report of one case managed with haloperidol]. ( Franco, JG; Valencia, C, 2008) |
| "The patients presented with visual hallucinations, disorientation, incomprehensible and nonsensical speech, and dilated sluggish pupils." | 1.34 | Teenagers with Jimson weed (Datura stramonium) poisoning. ( Spina, SP; Taddei, A, 2007) |
| "Upon treatment with diazepam and haloperidol, the psychosis subsided within three days." | 1.34 | [Postictal paranoid-hallucinatory psychosis in cryptogenic epilepsy]. ( Baum, P; Hermann, W; Kopf, A; Wagner, A, 2007) |
| " Carbamazepine at a dosage of 800 mg daily was the most effective medication used." | 1.33 | Auditory hallucinations after right temporal gyri resection. ( Brennan, DM; Stewart, B, 2005) |
| "The persistent auditory hallucinations were correlated with rapid eye movement sleep symptoms during her disease process so that we concluded that her persistent auditory hallucinations and delusion of observation were due to narcoleptic symptoms." | 1.31 | A narcoleptic patient exhibiting hallucinations and delusion. ( Maeda, H; Mukai, M; Sakamoto, T; Satomura, T; Takeuchi, N; Uchimura, N, 2000) |
| "Bromperidol 12 mg was prescribed to treat his symptoms." | 1.31 | [Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies]. ( Iwado, H; Morita, Y; Shinjo, H; Ueki, A, 2001) |
| "When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later." | 1.29 | Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. ( Dryden-Edwards, RC; Reiss, AL, 1996) |
| "The authors review the literature on tactile hallucinations." | 1.28 | A case study: schizophrenia and tactile hallucinations, treated with electroconvulsive therapy. ( England, RD; Salama, AA, 1990) |
| "Patients with paranoid schizophrenia display fully or partially unstable circadian rhythms." | 1.27 | [Treatment of paranoid schizophrenia taking circadian biological rhythms into account]. ( Tsaritsinskiĭ, VI, 1984) |
| "We report a patient in whom Tourette's syndrome (TS) and Type I schizophrenia coincided, and suggest, based on clinical features and pharmacological responses, that both conditions in this patient could have a common pathophysiological basis." | 1.27 | Gilles de la Tourette's syndrome associated with chronic schizophrenia. ( Bamford, CR; Sandyk, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (39.80) | 18.7374 |
| 1990's | 22 (22.45) | 18.2507 |
| 2000's | 21 (21.43) | 29.6817 |
| 2010's | 13 (13.27) | 24.3611 |
| 2020's | 3 (3.06) | 2.80 |
| Authors | Studies |
|---|---|
| Subramanyam, AA | 1 |
| Nachane, HB | 1 |
| Mahajan, NN | 1 |
| Shinde, S | 1 |
| D Mahale, S | 1 |
| Gajbhiye, RK | 1 |
| Schmack, K | 1 |
| Bosc, M | 1 |
| Ott, T | 1 |
| Sturgill, JF | 1 |
| Kepecs, A | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Harley, JA | 1 |
| Peebles, C | 1 |
| Porter, RJ | 1 |
| Fry, BR | 1 |
| Russell, N | 1 |
| Gifford, R | 1 |
| Robles, CF | 1 |
| Manning, CE | 1 |
| Sawa, A | 1 |
| Niwa, M | 1 |
| Johnson, AW | 1 |
| Elbakary, NAH | 1 |
| Ouanes, S | 1 |
| Emul, M | 1 |
| Sakalli, A | 1 |
| Erol, TC | 1 |
| Ertan, T | 1 |
| Ajiboye, PO | 1 |
| Yusuf, AD | 1 |
| Bouritius, EM | 1 |
| Neven, A | 1 |
| Blom, JD | 1 |
| Kamijo, Y | 1 |
| Mörkl, S | 1 |
| Blesl, C | 1 |
| Wurm, WE | 1 |
| Tmava, A | 1 |
| Stoller, A | 1 |
| Dolder, PC | 1 |
| Bodmer, M | 1 |
| Hammann, F | 1 |
| Rentsch, KM | 1 |
| Exadaktylos, AK | 1 |
| Liechti, ME | 1 |
| Liakoni, E | 1 |
| Valencia, C | 1 |
| Franco, JG | 1 |
| Iwata, K | 1 |
| Masuda, M | 1 |
| Soejima, K | 1 |
| Ohashi, M | 1 |
| Bagati, D | 1 |
| Nizamie, SH | 1 |
| Prakash, R | 1 |
| Felthous, AR | 1 |
| Wenger, PJ | 1 |
| Hoevet, R | 1 |
| Nguyen, H | 2 |
| Le, C | 1 |
| Makkos, Z | 1 |
| Fejes, L | 1 |
| Inczédy-Farkas, G | 1 |
| Kassai-Farkas, A | 1 |
| Faludi, G | 1 |
| Lazáry, J | 1 |
| Kashyap, GL | 1 |
| Patel, AG | 1 |
| Ueda, N | 1 |
| Terao, T | 1 |
| Ohmori, O | 1 |
| Nakamura, J | 1 |
| BOBON, J | 1 |
| COLLARD, J | 1 |
| DELREE, C | 1 |
| GERNAY, JM | 1 |
| VOLMAT, R | 1 |
| BEAUDOUIN, JL | 1 |
| COLLIN, J | 1 |
| NICOLAS-CHARLES, PJ | 1 |
| ALLERS, G | 1 |
| JACOB, E | 1 |
| MARIE, C | 1 |
| Ikeda, H | 1 |
| Yamamoto, M | 1 |
| Hashimoto, E | 1 |
| Saito, T | 1 |
| Uchida, H | 1 |
| Suzuki, T | 1 |
| Watanabe, K | 1 |
| Yagi, G | 1 |
| Kashima, H | 1 |
| Alevizos, B | 1 |
| Abe, K | 1 |
| Sluys, M | 1 |
| Güzelcan, Y | 1 |
| Casteelen, G | 1 |
| de Haan, L | 1 |
| Narumoto, J | 1 |
| Matsushima, N | 1 |
| Oka, S | 1 |
| Shimizu, H | 1 |
| Kooguchi, Y | 1 |
| Kitabayashi, Y | 1 |
| Kunizawa, M | 1 |
| Ueda, H | 1 |
| Fukui, K | 1 |
| Stewart, B | 1 |
| Brennan, DM | 1 |
| Mosolov, SN | 1 |
| Kabanov, S | 1 |
| Walter, RB | 1 |
| Hoofnagle, AN | 1 |
| Lanum, SA | 1 |
| Collins, SJ | 1 |
| Dávila, R | 1 |
| Zumárraga, M | 1 |
| Basterreche, N | 1 |
| Arrúe, A | 1 |
| Anguiano, JB | 1 |
| Spina, SP | 1 |
| Taddei, A | 1 |
| Yamamoto, N | 1 |
| Oda, T | 1 |
| Inada, T | 1 |
| Baum, P | 1 |
| Kopf, A | 1 |
| Hermann, W | 1 |
| Wagner, A | 1 |
| Bourguignon, A | 1 |
| Monfort, JC | 1 |
| de Medeiros, P | 1 |
| Cadet, B | 1 |
| Chaneac, D | 1 |
| Winter, M | 1 |
| Lehmann, E | 1 |
| Scholz, OB | 1 |
| Tsaritsinskiĭ, VI | 1 |
| Abraham, TM | 1 |
| Sato, M | 1 |
| Chen, CC | 1 |
| Akiyama, K | 1 |
| Otsuki, S | 1 |
| Shader, RI | 1 |
| Oesterheld, JR | 1 |
| Ibrahim, ZY | 1 |
| Carney, MM | 1 |
| Frieboes, RM | 1 |
| Müller, U | 1 |
| von Cramon, DY | 1 |
| Tényi, T | 1 |
| Trixler, M | 1 |
| John, S | 1 |
| Ovsiew, F | 1 |
| Suwaki, H | 1 |
| Miyatake, R | 1 |
| Dryden-Edwards, RC | 1 |
| Reiss, AL | 1 |
| Paul, KL | 1 |
| Bhatara, VS | 1 |
| Sanguineti, VR | 1 |
| Angelo, A | 1 |
| Frank, MR | 1 |
| Wolter-Henseler, DK | 1 |
| Devanand, DP | 1 |
| Marder, K | 1 |
| Michaels, KS | 1 |
| Sackeim, HA | 1 |
| Bell, K | 1 |
| Sullivan, MA | 1 |
| Cooper, TB | 1 |
| Pelton, GH | 1 |
| Mayeux, R | 1 |
| Kornreich, C | 1 |
| Dan, B | 1 |
| Verbanck, P | 1 |
| Pelc, I | 1 |
| Takeuchi, N | 1 |
| Mukai, M | 1 |
| Uchimura, N | 1 |
| Satomura, T | 1 |
| Sakamoto, T | 1 |
| Maeda, H | 1 |
| Benítez del Rosario, MA | 1 |
| Montón, F | 1 |
| Salinas, A | 1 |
| Martín, JJ | 1 |
| Feria, M | 1 |
| Marilov, VV | 1 |
| Ueki, A | 1 |
| Iwado, H | 1 |
| Shinjo, H | 1 |
| Morita, Y | 1 |
| Dobrzański, T | 1 |
| Pieschl, D | 1 |
| Ehle, G | 1 |
| Uebelhack, R | 1 |
| Dudley, DL | 1 |
| Rowlett, DB | 1 |
| Loebel, PJ | 1 |
| Cutler, NR | 1 |
| Heiser, JF | 1 |
| Rossner, M | 1 |
| König, L | 1 |
| Carter, RG | 1 |
| Miyakawa, T | 1 |
| Rüther, E | 2 |
| Schilkrut, R | 2 |
| Ackenheil, M | 2 |
| Eben, E | 2 |
| Hippius, H | 2 |
| Colonna, L | 1 |
| Singh, MM | 2 |
| Kay, SR | 1 |
| Cookson, IB | 1 |
| Owen, F | 1 |
| Ridges, AP | 1 |
| Janssen, P | 1 |
| Folkerts, H | 1 |
| Kuhs, H | 1 |
| Goldman, RS | 1 |
| Tandon, R | 1 |
| Liberzon, I | 1 |
| Goodson, J | 1 |
| Greden, JF | 1 |
| Nisijima, K | 1 |
| Hirayama, M | 1 |
| Nambudiri, DE | 1 |
| Young, RC | 1 |
| Kastrup, O | 1 |
| Eikmeier, G | 1 |
| Gastpar, M | 1 |
| Saletu, B | 1 |
| Küfferle, B | 1 |
| Anderer, P | 1 |
| Grünberger, J | 1 |
| Steinberger, K | 1 |
| Zemlan, FP | 1 |
| Thienhaus, OJ | 1 |
| Garver, DL | 1 |
| Salama, AA | 1 |
| England, RD | 1 |
| Friedman, EH | 1 |
| Fisher, W | 1 |
| Piazza, CC | 1 |
| Page, TJ | 1 |
| Sandyk, R | 1 |
| Bamford, CR | 1 |
| Chaturvedi, SK | 1 |
| Keats, MM | 1 |
| Mukherjee, S | 1 |
| Snyder, JW | 1 |
| Poe, RO | 1 |
| Stubbins, JF | 1 |
| Garrettson, LK | 1 |
| Schlör, KH | 1 |
| Moises, HW | 1 |
| Haas, S | 1 |
| Rieger, H | 1 |
| Man, PL | 1 |
| Petrova, ES | 1 |
| Duncan, JW | 1 |
| Angrist, B | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Gershon, S | 1 |
| Smith, JM | 1 |
| Eggers, C | 1 |
| Bazhin, EF | 1 |
| Rafalovich, EG | 1 |
| Moskowitz, D | 1 |
| Taylor, MA | 1 |
| Zolotnitskii, RI | 1 |
| Kutsenok, BM | 1 |
| Gastev, MD | 1 |
| de Barros-Ferreira, M | 1 |
| Mattos, E | 1 |
| Entin, GM | 1 |
| Lichko, AE | 1 |
| Marchenko, BV | 1 |
| Prakhov, VI | 1 |
| Radavichius, LI | 1 |
| Khaliavin, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
5 reviews available for haloperidol and Hallucination of Body Sensation
| Article | Year |
|---|---|
[Dangerous drugs: products containing synthetic chemicals].
Topics: Alkaloids; Antipsychotic Agents; Cannabinoids; Central Nervous System Diseases; Consciousness Disord | 2016 |
[Alcohol hallucinosis].
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Dopamine; Hallucinations | 2003 |
[Symptomatic acoustic hallucinations after traumatic brain damage. Review of the literature and case report].
Topics: Adult; Auditory Perceptual Disorders; Behavior Therapy; Brain Damage, Chronic; Brain Edema; Combined | 1994 |
[Alcoholic hallucinosis].
Topics: Antipsychotic Agents; Diagnosis, Differential; Hallucinations; Haloperidol; Humans; Psychoses, Alcoh | 1997 |
[Prepsychotic states in infancy (author's transl)].
Topics: Affective Symptoms; Age Factors; Child; Child Behavior Disorders; Child Development; Child, Preschoo | 1974 |
5 trials available for haloperidol and Hallucination of Body Sensation
| Article | Year |
|---|---|
Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Haloperidol; Humans; International Classificati | 2009 |
Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder.
Topics: Hallucinations; Haloperidol; Hostility; Humans; Hypochondriasis; Schizophrenia; Schizophrenia, Paran | 1984 |
A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
Topics: Aged; Aggression; Alzheimer Disease; Ambulatory Care; Basal Ganglia Diseases; Brief Psychiatric Rati | 1998 |
Therapeutic reversal with benxtropine in schizophrenics. Practical and theoretical significance.
Topics: Adult; Affect; Attention; Benztropine; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; Dr | 1975 |
Sleeplessness in acute and chronic schizophrenia--response to haloperidol and anti-parkinsonism agents.
Topics: Acute Disease; Adult; Antiparkinson Agents; Arousal; Benztropine; Chronic Disease; Clinical Trials a | 1973 |
88 other studies available for haloperidol and Hallucination of Body Sensation
| Article | Year |
|---|---|
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.
Topics: Antipsychotic Agents; Asymptomatic Infections; COVID-19; Delusions; Female; Hallucinations; Haloperi | 2020 |
Striatal dopamine mediates hallucination-like perception in mice.
Topics: Animals; Auditory Perception; Corpus Striatum; Dopamine; Female; Hallucinations; Haloperidol; Humans | 2021 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Electroconvulsive therapy for catatonia secondary to neuroleptic malignant syndrome in a patient with multiple sclerosis.
Topics: Adult; Antipsychotic Agents; Catatonia; Electroconvulsive Therapy; Female; Hallucinations; Haloperid | 2019 |
Assessing Reality Testing in Mice Through Dopamine-Dependent Associatively Evoked Processing of Absent Gustatory Stimuli.
Topics: Animals; Antipsychotic Agents; Association Learning; Auditory Perception; Behavior, Animal; Cerebral | 2020 |
First generation antipsychotic-induced severe hypothermia: A case report and review of the literature.
Topics: Antipsychotic Agents; Chlorpromazine; Diagnosis, Differential; Drug Administration Schedule; Female; | 2019 |
Thyrotoxic psychosis in an elderly woman and haloperidol use: a case report.
Topics: Antipsychotic Agents; Antithyroid Agents; Apathy; Diagnosis, Differential; Female; Hallucinations; H | 2013 |
Monosymptomatic Hypochondriacal Psychosis (somatic delusional disorder): a report of two cases.
Topics: Adult; Affective Disorders, Psychotic; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychoti | 2013 |
[Alcohol hallucinosis].
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Antipsychotic Agents; Diagnosis, Differential; Hallu | 2015 |
[Acute Psychosis after Consumption of Synthetic Cannabinoids].
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cannabinoids; Hallucinations; Haloperidol; Humans; Hy | 2016 |
Mistaking 2C-P for 2C-B: What a Difference a Letter Makes.
Topics: Antipsychotic Agents; Benzodiazepines; Chemical Phenomena; Chromatography, Liquid; Dimethoxyphenylet | 2017 |
[Charles Bonnet syndrome: report of one case managed with haloperidol].
Topics: Aged, 80 and over; Antipsychotic Agents; Diagnosis, Differential; Female; Hallucinations; Haloperido | 2008 |
Combination of electroconvulsive therapy with skin graft surgery for a schizophrenic patient with burns.
Topics: Anesthesia; Antipsychotic Agents; Burns; Drug Resistance; Electroconvulsive Therapy; Hallucinations; | 2009 |
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Ha | 2010 |
Charles Bonnet syndrome in an elderly patient concurrent with acute cerebellar infarction treated successfully with haloperidol.
Topics: Aged; Brain Infarction; Cerebellar Diseases; Dopamine Antagonists; Hallucinations; Haloperidol; Huma | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diben | 2011 |
Unusual presentation of a patient with GBL withdrawal: a case report.
Topics: 4-Butyrolactone; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chlorpromazine; Delirium; Hal | 2011 |
Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Delusions; Diagnosis, Differe | 2003 |
[SPIROPERIDOL].
Topics: Catatonia; Geriatrics; Hallucinations; Haloperidol; Humans; Hypnotics and Sedatives; Paranoid Disord | 1963 |
[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Delirium; Depression; Hallucinations; Halope | 1964 |
[Importance of R 1625 (Haloperidol) in the treatment of chronic hallucinatory psychoses].
Topics: Electroconvulsive Therapy; Hallucinations; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psyc | 1961 |
Antipsychotic-induced paroxysmal perceptual alteration.
Topics: Antipsychotic Agents; Anxiety Disorders; Drug Therapy, Combination; Female; Hallucinations; Haloperi | 2003 |
Dependence and chronic psychosis with D-nor-pseudoephedrine.
Topics: Antipsychotic Agents; Appetite; Appetite Depressants; Benzodiazepines; Central Nervous System Stimul | 2003 |
Antipsychotic medications can induce transient psychotic episodes without oculogyric crises.
Topics: Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 2004 |
Risperidone-induced leucopenia and neutropenia: a case report.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Dementia, Vascular; Hallucinations; Halope | 2004 |
Neurobehavioral changes associated with bilateral caudate nucleus infarctions.
Topics: Basal Ganglia Cerebrovascular Disease; Caudate Nucleus; Cerebral Cortex; Cerebral Infarction; Delusi | 2005 |
Auditory hallucinations after right temporal gyri resection.
Topics: Adult; Affect; Anticonvulsants; Antipsychotic Agents; Brain Injuries; Carbamazepine; Electroencephal | 2005 |
Quetiapine in the treatment of patients with resistant auditory hallucinations: two case reports with long-term cognitive assessment.
Topics: Adult; Antipsychotic Agents; Auditory Perception; Cognition; Dibenzothiazepines; Female; Hallucinati | 2005 |
Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient.
Topics: Anti-Infective Agents; Glucose; Hallucinations; Haloperidol; Hematopoietic Stem Cell Transplantation | 2006 |
Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Depression; Dopamine; Female; Hallucinations; Haloperidol; | 2007 |
Teenagers with Jimson weed (Datura stramonium) poisoning.
Topics: Adolescent; Anti-Anxiety Agents; Antipsychotic Agents; Cholinergic Antagonists; Confusion; Datura st | 2007 |
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Biperiden; Central Nervous Syst | 2007 |
[Postictal paranoid-hallucinatory psychosis in cryptogenic epilepsy].
Topics: Acute Disease; Adult; Anticonvulsants; Cooperative Behavior; Delusions; Diazepam; Epilepsy; Epilepsy | 2007 |
[Treatment of several psychotic states with the combination of valproic acid with diazepam].
Topics: Acute Disease; Adult; Delusions; Diazepam; Drug Therapy, Combination; Female; Hallucinations; Halope | 1984 |
[Treatment of paranoid schizophrenia taking circadian biological rhythms into account].
Topics: Adolescent; Adult; Blood Pressure; Body Temperature; Circadian Rhythm; Delusions; Female; Hallucinat | 1984 |
Unusual presentation after an overdose of haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Hallucinations; Haloperidol; Humans; Male | 1984 |
Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis.
Topics: Adult; Delusions; Hallucinations; Haloperidol; Humans; Male; Methamphetamine; Paranoid Disorders; Ps | 1983 |
Canny cases. Case 5: the dextral dodder.
Topics: Adult; Auditory Perception; Female; Hallucinations; Haloperidol; Humans; Schizophrenia | 1995 |
Safe use of haloperidol in acute intermittent porphyria.
Topics: Acute Disease; Adult; Confusion; Hallucinations; Haloperidol; Humans; Male; Porphyria, Acute Intermi | 1995 |
Coexistence of the delusions of infestation and body smell in schizophrenia: a case report.
Topics: Combined Modality Therapy; Delusions; Ectoparasitic Infestations; Female; Hallucinations; Haloperido | 1993 |
Erotomania in a brain-damaged male.
Topics: Adult; Brain Damage, Chronic; Delusions; Hallucinations; Haloperidol; Humans; Intellectual Disabilit | 1996 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinatio | 1996 |
Anticholinergic delirium possibly associated with protriptyline and fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cholinergic Antagonists; | 1997 |
GHB: a home brew.
Topics: Anesthetics, Intravenous; Antipsychotic Agents; Hallucinations; Haloperidol; Hospitalization; Humans | 1997 |
[Optical hallucinosis during benzodiazepine withdrawal in low-dose dependence].
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Hallucina | 1997 |
Treating Charles Bonnet syndrome: understanding inconsistency.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Psychotic | 2000 |
A narcoleptic patient exhibiting hallucinations and delusion.
Topics: Delusions; Diagnosis, Differential; Female; Hallucinations; Haloperidol; Humans; Middle Aged; Narcol | 2000 |
Charles Bonnet syndrome and opioids.
Topics: Aged; Analgesics, Opioid; Antipsychotic Agents; Blindness; Diagnosis, Differential; Fatal Outcome; H | 2001 |
[The Dolittle syndrome].
Topics: Adult; Animals; Antipsychotic Agents; Birds; Cats; Female; Hallucinations; Haloperidol; Humans; Schi | 1997 |
[Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies].
Topics: Aged; Donepezil; Drug Therapy, Combination; Hallucinations; Haloperidol; Humans; Indans; Lewy Body D | 2001 |
[Plasma ACTH, STH and other hormone levels in various groups under chlormethiazole, haloperidol or reserpine load in alchohol delirium, alcoholic hallucinations, and chronic alcoholism].
Topics: 17-Hydroxycorticosteroids; Adrenocorticotropic Hormone; Alcohol Withdrawal Delirium; Alcoholism; Blo | 1976 |
[Dangerous side effects of lithium therapy].
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Brain Stem; Delirium; Diabetes Insipidus; D | 1977 |
Emergency use of intravenous haloperidol.
Topics: Adult; Bipolar Disorder; Emergency Services, Psychiatric; Female; Hallucinations; Haloperidol; Human | 1979 |
Leukopenia following treatment with thiothixene and haloperidol.
Topics: Adult; Hallucinations; Haloperidol; Humans; Leukopenia; Male; Thiothixene | 1979 |
[Neuroleptic long term care with extremely low doses in psychotic syndromes of paranoid-hallucination type].
Topics: Dose-Response Relationship, Drug; Hallucinations; Haloperidol; Humans; Long-Term Care; Paranoid Diso | 1975 |
Psychotolysis with haloperidol. Rapid control of the acutely disturbed psychotic patient.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Conflict, Psychological; Female; Hallucina | 1977 |
Investigation concerning hallucinatory and delusional states--in connection with hypofunction of brain stem and diencephalon.
Topics: Arousal; Brain Stem; Consciousness Disorders; Delusions; Diencephalon; Electroencephalography; Hallu | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
Topics: Adult; Female; Hallucinations; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
Topics: Adult; Aged; Brain Damage, Chronic; Depression; Female; Hallucinations; Haloperidol; Homovanillic Ac | 1976 |
[Paradoxical effects of neuroleptics].
Topics: Adult; Female; Hallucinations; Haloperidol; Humans; Male; Middle Aged; Tranquilizing Agents | 1976 |
Platelet monoamine oxidase activity during the course of a schizophreniform psychosis.
Topics: Blood Platelets; Cognition Disorders; Delusions; Emotions; Hallucinations; Haloperidol; Humans; Male | 1975 |
The "social chemistry" of pharmacological discovery: the haloperidol story. An interview with Dr. Paul Janssen, January 21, 1986. Interview by Stanley Einstein.
Topics: Animals; Female; Hallucinations; Haloperidol; Humans; Male; Rats; Schizophrenia; Schizophrenic Psych | 1992 |
[Psychotic episode caused by prevention of malaria with mefloquine. A case report].
Topics: Adult; Female; Hallucinations; Haloperidol; Humans; Malaria; Mefloquine; Perazine; Psychoses, Substa | 1992 |
Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia.
Topics: Adult; Arousal; Chlorpromazine; Delusions; Female; Hallucinations; Haloperidol; Humans; Male; Psychi | 1991 |
[ICU syndrome].
Topics: Aged; Anxiety; Benzodiazepines; Clomipramine; Critical Care; Delirium; Depressive Disorder; Female; | 1991 |
A case of late-onset crack dependence and subsequent psychosis in the elderly.
Topics: Crack Cocaine; Delusions; Hallucinations; Haloperidol; Humans; Male; Middle Aged; Psychoses, Substan | 1991 |
[Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses].
Topics: Akathisia, Drug-Induced; Biperiden; Diagnosis, Differential; Doxepin; Dysarthria; Dyskinesia, Drug-I | 1991 |
EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol.
Topics: Adult; Antipsychotic Agents; Behavior; Benzamides; Brain Mapping; Electroencephalography; Female; Ha | 1990 |
Length of psychiatric hospitalization and prediction of antipsychotic response.
Topics: Fluphenazine; Hallucinations; Haloperidol; Hospitalization; Humans; Length of Stay; Prognosis; Schiz | 1990 |
A case study: schizophrenia and tactile hallucinations, treated with electroconvulsive therapy.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Delusions; Electroconvulsive Therapy; Hallucinati | 1990 |
Treatment of tardive dystonia.
Topics: Auditory Perceptual Disorders; Dystonia; Hallucinations; Haloperidol; Humans; Infant; Ocular Motilit | 1990 |
Assessing independent and interactive effects of behavioral and pharmacologic interventions for a client with dual diagnoses.
Topics: Autistic Disorder; Behavior Therapy; Child; Combined Modality Therapy; Follow-Up Studies; Hallucinat | 1989 |
Gilles de la Tourette's syndrome associated with chronic schizophrenia.
Topics: Adolescent; Chronic Disease; Hallucinations; Haloperidol; Humans; Male; Naltrexone; Schizophrenia, P | 1988 |
Coprophagia in a schizophrenic patient: case report.
Topics: Adult; Combined Modality Therapy; Delusions; Electroconvulsive Therapy; Female; Hallucinations; Halo | 1988 |
Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder.
Topics: Adult; Aggression; Clonazepam; Drug Therapy, Combination; Electroconvulsive Therapy; Epilepsy, Tempo | 1988 |
Acute manic psychosis following the dermal application of N,N-diethyl-m-toluamide (DEET) in an adult.
Topics: Administration, Topical; Adult; Benzamides; Bipolar Disorder; DEET; Hallucinations; Haloperidol; Hot | 1986 |
Schizophrenia, psychoticism, neuroleptics, and auditory evoked potentials.
Topics: Adult; Arousal; Evoked Potentials, Auditory; Female; Hallucinations; Haloperidol; Humans; Male; Pers | 1985 |
Long-term effects of haloperidol.
Topics: Adolescent; Adult; Back Pain; Basal Ganglia Diseases; Bipolar Disorder; Depression; Depressive Disor | 1973 |
[Hallucinatory paraphrenic syndrome in the course of schizophrenia].
Topics: Adult; Automatism; Azo Compounds; Delirium; Hallucinations; Haloperidol; Humans; Illusions; Paranoid | 1967 |
Persisting psychotic states in adolescent drug users.
Topics: Adolescent; Cataplexy; Child, Institutionalized; Chlorpromazine; Delusions; Hallucinations; Hallucin | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
[Treatment of hallucinatory disorders in schizophrenia with atropine comas].
Topics: Amitriptyline; Atropine; Chlorpromazine; Coma; Drug Therapy, Combination; Epinephrine; Hallucination | 1973 |
Use of haloperidol to reduce LSD flashbacks.
Topics: Hallucinations; Haloperidol; Humans; Lysergic Acid Diethylamide; Male; Naval Medicine; Psychoses, Su | 1971 |
Schneiderian first-rank symptoms and clinical prognostic features in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Auditory Perception; Delusions; Diagnosis, Differential; Hallucinati | 1972 |
[On the results of treatment and complications during the use of haloperidol in patients with long-term schizophrenia].
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Catatonia; Chlorpromazine; Cognition Disorders; Hall | 1969 |
[Developmental study on night sleep during episodes of manias or acute depressions].
Topics: Acute Disease; Adult; Bipolar Disorder; Chlorpromazine; Delirium; Electroencephalography; Female; Ha | 1969 |
[The clinical picture and therapy of alcoholic psychoses in old age].
Topics: Acute Disease; Apomorphine; Barbiturates; Cerebrovascular Disorders; Delirium; Delusions; Female; Ha | 1970 |
[Features of a reaction to intravenous haloperidol administration].
Topics: Adult; Aggression; Alcoholism; Anxiety; Depression; Hallucinations; Haloperidol; Humans; Injections, | 1971 |